



Round Table Report

1 February 2021

For restricted use

This report summarizes the ECDC daily roundtable discussion and provides update on threats detected and monitored by Epidemic Intelligence.

Active threats

COVID-19 associated with SARS-CoV-2 – multi-country (world) – 2019-2021

COVID-19 Vaccine

EMA has authorised the AstraZeneca vaccine for use across the EU for people aged 18 years and above. The AstraZeneca vaccine is now the third vaccine authorised by EMA. Combined results from four clinical trials in the United Kingdom, Brazil and South Africa showed that the COVID-19 Vaccine AstraZeneca was safe and effective at preventing COVID-19 in people aged 18 years and above. The vaccine is to be given as two standard doses.

SARS-CoV-2 variants - Multi-country (World) - 2020-2021

As of 01 February 2021, according to media and official sources, the variant **VOC 202012/01** has been identified in 73 countries. Since its identification and as of 01 February 2021, approximately 38 900 cases have been identified.

In the EU/EEA, around 2 700 cases have been identified in 26 countries: Denmark (561), Spain (324), Netherlands (323), France (299), Belgium (194), Greece (173), Ireland (165), Italy (134), Portugal (114), Finland (88), Norway (65), Germany (60), Austria (42), Iceland (37), Slovakia (37), Sweden (15), Czechia (13), Cyprus (12), Romania (9), Hungary (5), Latvia (5), Luxembourg (3), Malta (3), Liechtenstein (1), Poland (1) and Slovenia (1).

Outside the EU/EEA, approximately 36 200 cases have been identified in 47 countries: United Kingdom (34 758), United States of America (467), Switzerland (192), India (150), Israel (147), Australia (62), Turkey (51), Jordan (38), Japan (34), Singapore (34), New Zealand (26), Canada (24), United Arab Emirates (23), Chile (20), South Korea (19), Philippines (17), Brazil (11), Saudi Arabia (10), Taiwan (7), China (6), Ecuador (6), Iran (4), Jamaica (4), Thailand (4), Nepal (3), Pakistan (3), Russia (3), 5.1.2e 5.1.2e (3), Gambia (2), Argentina (1), Bangladesh (1), Georgia (1), Kuwait (1), Lebanon (1), Malaysia (1), Mexico (1), Morocco (1), Nigeria (1), North Macedonia (1), Oman (1), Panama (1), Peru (1), Senegal (1), Serbia (1), Sri Lanka (1), Trinidad and Tobago (1) and Vietnam (1).

As of 01 February 2021, according to media and official sources, the variant **501.V2** has been identified in 33 countries. Since its identification and as of 01 February 2021, approximately 850 cases have been identified.

In the EU/EEA, around 140 cases have been identified in 13 countries: France (40), Netherlands (22), Belgium

1/3

(21), Austria (19), Germany (17), Ireland (9), Denmark (4), Finland (2), Greece (1), Norway (1), Portugal (1), Spain (1) and Sweden (1).

Outside the EU/EEA, approximately 710 cases have been identified in 20 countries: South Africa (524), United Kingdom (94), Mozambique (19), Israel (12), Switzerland (10), Australia (8), Botswana (7), New Zealand (7), United Arab Emirates (5), Japan (4), United States of America (3), Canada (2), China (2), Kenya (2), South Korea (2), Brazil (1), Serbia (1), Taiwan (1) and Zambia (1).

As of 01 February 2021, according to media and official sources, the variant **P.1** has been identified in 9 countries. Since its identification and as of 01 February 2021, approximately 60 cases have been identified.

In the EU/EEA, 5 cases have been identified in 2 countries: Italy (4) and Germany (1).

Outside the EU/EEA, approximately 50 cases have been identified in 7 countries: Brazil (30), United Kingdom (9), Japan (4), Colombia (1), Faroe Islands (1), South Korea (1) and United States of America (1).

buiten verzoek

3 - 3

buiten verzoek